LexaGene Files for Chapter 7 Bankruptcy
February 24, 2023 08:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), announces that it has ceased operations, laid off its staff, and,...
LexaGene Holdings Announces Results of February 8, 2023 Annual General Meeting
February 10, 2023 14:17 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...
LexaGene Provides Update on BioPharma Sector
February 08, 2023 08:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customers
January 18, 2023 08:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
BioPharma Engages LexaGene in Second Feasibility Study
December 16, 2022 08:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass. , Dec. 16, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene Holdings Proposes to Amend Warrants Terms
December 07, 2022 08:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene Successfully Completes Statement of Work for BioPharma Company
November 22, 2022 08:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene Closes Secured Convertible Note Transaction
November 01, 2022 16:01 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...
LexaGene Holdings Proposes to Amend Warrants Terms
October 27, 2022 17:18 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...
LexaGene Enters into Secured Convertible Note Agreement
October 24, 2022 08:00 ET
|
LexaGene Holdings Inc
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. BEVERLY, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings,...